Fusion protein for use in the treatment of hvg disease
AssigneesMedizinische Hochschule Hannover, Technische Universität Braunschweig
InventorsElmar Jäckel, Fatih Noyan, Michael Hust
Life of this patent
Estimating the term…
Abstract
The invention provides a fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02 or SLA-01*0401.
Claims21
Fusion protein comprising a single-chain variable fragment antibody domain (scFv), a hinge, a transmembrane domain, an intracellular hCD28 signalling domain and an intracellular hCD3ζ (hCD3 zeta) signalling domain forming a chimeric antigen receptor having specificity for HLA-A*02 (CAR-A*02) or having specificity for SLA-01*0401 (CAR-SLA-01*0401) for use in the treatment of HvG disease in a patient, the single-chain variable fragment antibody domain (scFv) having an amino acid sequence which is selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 12 or SEQ ID NO:
- 16 to SEQ ID NO:
- 19.
Dependencies are inferred from the claim text.